Strategic use of new generation antidepressants for depression: SUN(^_^)D study protocol
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
BACKGROUND: After more than half a century of modern psychopharmacology, with billions of dollars spent on antidepressants annually world-wide, we lack good evidence to guide our everyday decisions in conducting antidepressant treatment of patients with major depression. First we did not know which antidepressant to use as first line treatment. Second we do not know which dosage we should be aiming at with that antidepressant. Because more than half of the patients with major depression starting treatment do not remit after adequate trial with the first agent, they will need a second line treatment. Dose escalation, augmentation and switching are the three often recommended second line strategies but we do not know which is better than the others. Moreover, we do not know when to start considering this second line treatment.The recently published multiple-treatments meta-analysis of 12 new generation antidepressants has provided some partial answers to the first question. Starting with these findings, this proposed trial aims to establish the optimum 1st line and 2nd line antidepressant treatment strategy among adult patients with a non-psychotic unipolar major depressive episode. METHODS: SUN(^_^)D, the Strategic Use of New generation antidepressants for Depression, is an assessor-blinded, parallel-group, multi-centre randomised controlled trial. Step I is a cluster-randomised trial comparing titration up to the minimum vs maximum of the recommended dose range among patients starting with sertraline. The primary outcome is the change in the Patient Health Questionnaire (PHQ)-9 scores administered by a blinded rater via telephone at week 1 through 3. Step II is an individually randomised trial comparing staying on sertraline, augmentation of sertraline with mirtazapine, and switching to mirtazapine among patients who have not remitted on the first line treatment by week 3. The primary outcome is the change in the PHQ-9 scores at week 4 through 9. Step III represents a continuation phase to Steps I and II and aims to establish longer-term effectiveness and acceptability of the above-examined treatment strategies up to week 25. The trial is supported by the Grant-in-Aid by the Ministry of Health, Labour and Welfare, Japan. DISCUSSION: SUN(^_^)D promises to be a pragmatic large trial to answer important clinical questions that every clinician treating patients with major depression faces in his/her daily practices concerning its first- and second-line treatments. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01109693.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Our information unfortunately cannot guide next-step choices after failure of such a first step (ie, they do not apply to treatment-resistant depression), for which well performed trials are scarce.29”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Power Analysis for the Behavioral Sciences
Muller, K. (1989) · Technometrics · doi:10.1080/00401706.1989.10488618 · Cited by 99,167
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation
Beck, A. T., Steer, R. A., & Carbin, M. G. (1988) · Clinical Psychology Review · doi:10.1016/0272-7358(88)90050-5 · Cited by 11,696 · cited 1×
“In its 40 years of usage, the BDI has become one of the most widely used instruments for detecting possible depression in normal populations and for assessing severity of depression in diagnosed patients [44].”
MethodSpitzer, R. L. (1999) · JAMA · doi:10.1001/jama.282.18.1737 · Cited by 9,802
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988 · cited 1×
“6% lifetime prevalence for American women and men [2] and with 16.”
BackgroundCohen, J. (1992) · Current Directions in Psychological Science · doi:10.1111/1467-8721.ep10768783 · Cited by 5,870
Higgins, S. M. F., Macken, A. P., Cullen, W., Saunders, J., Dunne, C. P., & O’Gorman, C. S. (2013) · PubMed · doi:10.34961/9953 · Cited by 4,806
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 1×
“return to an euthymic state, after treatment with an adequate dose of antidepressant given for an adequate duration [14].”
BackgroundSelective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
The ESEMeD/MHEDEA 2000 Investigators, Alonso, J., Angermeyer, M. C., Bernert, S., Bruffaerts, R., Brugha, T. S., Bryson, H., de Girolamo, G., de Graaf, R., Demyttenaere, K., et al. (2004) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0047.2004.00327.x · Cited by 1,819
Research works printed but not linked: 3
- NICE: Depression: the treatment and management of depression in adults (partial update of NICE clinical guideline 23). 2009, London: National Institute for Clinical Excellence
- Motohashi N, (Ed): Pharmacotherapy Algorithms for Mood Disorders. 2003, Tokyo: Jihou
- Beck AT, Steer RA, Brown GK: BDI-II: Beck Depression Inventory, Second Edition, Manual. 1996, San Antonia: The Psychological Corporation
Cited by
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Self-citationCipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · Focus · doi:10.1176/appi.focus.16407 · Cited by 328
Self-citationPharmacological interventions for treatment-resistant depression in adults
Davies, P., Ijaz, S., Williams, C. J., Kessler, D., Lewis, G., & Wiles, N. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010557.pub2 · Cited by 73
for the SUN☺D Investigators, Kato, T., Furukawa, T. A., Mantani, A., Kurata, K., Kubouchi, H., Hirota, S., Sato, H., Sugishita, K., Chino, B., et al. (2018) · BMC Medicine · doi:10.1186/s12916-018-1096-5 · Cited by 61
Self-citationChen, C., & Shan, W. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.112595 · Cited by 49
Metadata
- Authors
- Furukawa, T. A., Akechi, T., Shimodera, S., Yamada, M., Miki, K., Watanabe, N., Inagaki, M., & Yonemoto, N.
- Affiliations
- Kyoto University (JP)
- Nagoya City University (JP)
- Kochi Medical School Hospital (JP)
- National Center of Neurology and Psychiatry (JP)
- Corresponding author
- Furukawa, Toshi A
- ORCID
- Venue
- Trials
- Published
- 2011-05-11
- Volume
- 12
- Issue
- 1
- Pages
- 116-116
- ISSN
- 1745-6215 (ISSN-L)
- PMC
- PMC3120681
- OpenAlex
- W2165827913
- Cited by
- 23
- References
- 60
- Citations by year
- 2024: 1 · 2021: 1 · 2020: 1 · 2019: 5 · 2018: 4 · 2015: 1 · 2014: 1 · 2013: 6 · 2012: 1
- FWCI
- 2.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0 (tdm)
- Locations
- Trials (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Kyoto University Research Information Repository (Kyoto University) (submittedVersion, cc-by)
- Funders
- Ministry of Health, Labour and Welfare
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- major depressive disorder, first-line antidepressants, second-line therapy, dose titration, sertraline, mirtazapine, antidepressant augmentation, antidepressant switching, treatment-resistant depression, remission, PHQ-9
- MeSH terms
- Mirtazapine, Adult, Aged, Antidepressive Agents, Antidepressive Agents, Tricyclic, Major Depressive Disorder, Depressive Disorder, Major, Drug Administration Schedule, Female, Humans, Japan, Male, Mianserin, Middle Aged, Psychiatric Status Rating Scales, Surveys and Questionnaires, Research Design, Time Factors, Cluster Analysis, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Patient Selection, Sertraline, Drug Substitution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Strategic use of new generation antidepressants for depression: SUN(^_^)D study protocol. https://app.cochat.ai/papers/10.1186/1745-6215-12-116
- The paper
- Furukawa, T. A., Akechi, T., Shimodera, S., Yamada, M., Miki, K., Watanabe, N., Inagaki, M., & Yonemoto, N. (2011). Strategic use of new generation antidepressants for depression: SUN(^_^)D study protocol. Trials. https://doi.org/10.1186/1745-6215-12-116
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


